Left ventricular stiffening as therapeutic target for heart failure with preserved ejection fraction

Circulation Journal

Volumn 77, Issue 4, 2013, Pages 886-892

  Sakata, Yasushi ^a   Ohtani, Tomohito ^a   Takeda, Yasuharu ^a   Yamamoto, Kazuhiro ^b   Mano, Toshiaki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Diastolic dysfunction; Heart failure; Ventricular function

Indexed keywords

ACYL COENZYME A DESATURASE 1; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANOSINE PHOSPHATE; MATRIX METALLOPROTEINASE; MINERALOCORTICOID ANTAGONIST;

ARTERIAL STIFFNESS; CARDIOVASCULAR PARAMETERS; DOPPLER ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART PACING; HUMAN; LEFT VENTRICLE STIFFENING; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LUNG EDEMA; MITRAL VALVE; NONHUMAN; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TIME OF FLIGHT MASS SPECTROMETRY;

ANIMALS; BLOOD PRESSURE; DIASTOLE; DISEASE MODELS, ANIMAL; HEART ATRIA; HEART FAILURE; HEART VENTRICLES; MALE; PREVALENCE; PULMONARY EDEMA; PULMONARY VEINS; STROKE VOLUME;

EID: 84875551912     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0214     Document Type: Review

References (68)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology: Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
2. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
3. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-1900.
4. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269.
5. Rihal CS, Nishimura RA, Hatle LK, Bailey KR, Tajik AJ. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy: Relation to symptoms and prognosis. Circulation 1994; 90: 2772-2779.
6. Yamamoto K, Sakata Y, Ohtani T, Takeda Y, Mano T. Heart failure with preserved ejection fraction: Is it due to contractile dysfunction?: Reply. Circ J 2009; 73: 1170.
7. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure: Abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-1959.
8. Gilbert JC, Glantz SA. Determinants of left ventricular filling and of the diastolic pressure-volume relation. Circ Res 1989; 64: 827-852.
9. Mirsky I. Assessment of diastolic function: Suggested methods and future considerations. Circulation 1984; 69: 836-841.
10. Leite-Moreira AF. Current perspectives in diastolic dysfunction and diastolic heart failure. Heart 2006; 92: 712-718.
11. Hay I, Rich J, Ferber P, Burkhoff D, Maurer MS. Role of impaired myocardial relaxation in the production of elevated left ventricular filling pressure. Am J Physiol Heart Circ Physiol 2005; 288: H1203-H1208.
12. Doi R, Masuyama T, Yamamoto K, Doi Y, Mano T, Sakata Y, et al. Development of different phenotypes of hypertensive heart failure: Systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens 2000; 18: 111-120.
13. Masuyama T, Yamamoto K, Sakata Y, Doi R, Nishikawa N, Kondo H, et al. Evolving changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy. J Am Coll Cardiol 2000; 36: 2333-2338.
14. Sakata Y, Masuyama T, Yamamoto K, Doi R, Mano T, Kuzuya T, et al. Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: Different characteristics from renin angiotensin system-independent hypertrophy. J Am Coll Cardiol 2001; 37: 293-299.
15. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Miwa T, et al. Temocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction. Cardiovasc Res 2003; 57: 757-765.
16. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: A guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 2005; 289: H501-H512.
17. Mirsky I. Assessment of passive elastic stiffness of cardiac muscle: Mathematical concepts, physiologic and clinical considerations, directions of future research. Prog Cardiovasc Dis 1976; 18: 277-308.
18. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-2550.
19. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's rosetta stone. J Am Coll Cardiol 1997; 30: 8-18.
20. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: A noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527-1533.
21. Garcia MJ, Thomas JD, Klein AL. New doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32: 865-875.
22. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, et al. Clinical utility of doppler echocardiography and tissue doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 2000; 102: 1788-1794.
23. Nagueh SF, Lakkis NM, Middleton KJ, Spencer WH 3rd, Zoghbi WA, Quinones MA. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999; 99: 254-261.
24. Geske JB, Sorajja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: Correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation 2007; 116: 2702-2708.
25. Lester SJ, Tajik AJ, Nishimura RA, Oh JK, Khandheria BK, Seward JB. Unlocking the mysteries of diastolic function: Deciphering the Rosetta stone 10 years later. J Am Coll Cardiol 2008; 51: 679-689.
26. Ogunyankin KO. Assessment of left ventricular diastolic function: The power, possibilities, and pitfalls of echocardiographic imaging techniques. Can J Cardiol 2011; 27: 311-318.
27. Takeda Y, Sakata Y, Higashimori M, Mano T, Nishio M, Ohtani T, et al. Noninvasive assessment of wall distensibility with the evaluation of diastolic epicardial movement. J Card Fail 2009; 15: 68-77.
28. Aizawa Y, Sakata Y, Mano T, Takeda Y, Ohtani T, Tamaki S, et al. Transition from asymptomatic diastolic dysfunction to heart failure with preserved ejection fraction: Roles of systolic function and ventricular distensibility. Circ J 2011; 75: 596-602.
29. Takeda Y, Sakata Y, Mano T, Ohtani T, Kamimura D, Tamaki S, et al. Competing risks of heart failure with preserved ejection fraction in diabetic patients. Eur J Heart Fail 2011; 13: 664-669.
30. Ohtani T, Mohammed SF, Yamamoto K, Dunlay SM, Weston SA, Sakata Y, et al. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. Eur Heart J 2012; 33: 1742-1749.
31. Klotz S, Hay I, Zhang G, Maurer M, Wang J, Burkhoff D. Development of Heart failure in chronic hypertensive dahl rats: Focus on heart failure with preserved ejection fraction. Hypertension 2006; 47: 901-911.
32. Aurigemma GP, Gaasch WH. Clinical practice: Diastolic heart failure. N Engl J Med 2004; 351: 1097-1105.
33. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004; 43: 731-738.
34. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32: 670-679.
35. Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, et al. Prognostic impact of myocardial interstitial fibrosis in nonischemic heart failure: Comparison between preserved and reduced ejection fraction heart failure. Circ J 2011; 75: 2605-2613.
36. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002; 55: 76-82.
37. Nishikawa N, Masuyama T, Yamamoto K, Sakata Y, Mano T, Miwa T, et al. Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. J Am Coll Cardiol 2001; 38: 1539-1545.
38. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Nakayama H, et al. Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca(2+) regulatory proteins and extracellular matrix. J Hypertens 2003; 21: 1737-1745.
39. Nishikawa N, Yamamoto K, Sakata Y, Mano T, Yoshida J, Miwa T, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 2003; 57: 766-774.
40. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089-2096.
41. Gonzalez A, Lopez B, Querejeta R, Zubillaga E, Echeverria T, Diez J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010; 55: 1418-1424.
42. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005; 112: 1136-1144.
43. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153: 937-942.
44. Timmermans PB. Angiotensin II receptor antagonists: An emerging new class of cardiovascular therapeutics. Hypertens Res 1999; 22: 147-153.
45. Yalcin F, Aksoy FG, Muderrisoglu H, Sabah I, Garcia MJ, Thomas JD. Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function. Clin Cardiol 2000; 23: 437-441.
46. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-2517.
47. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-2345.
48. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARMPRESERVED trial. Lancet 2003; 362: 777-781.
49. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
50. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341: 709-717.
51. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 2007; 292: R946-R954.
52. Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, et al. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail 2013; 1: 40-47.
53. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
54. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13.
55. Nishio M, Sakata Y, Mano T, Ohtani T, Takeda Y, Miwa T, et al. Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail 2008; 10: 446-453.
56. Kobayashi M, Machida N, Mitsuishi M, Yamane Y. Beta-blocker improves survival, left ventricular function and myocardial remodeling in hypertensive rats with diastolic heart failure. Am J Hypertens 2004; 17: 1112-1119.
57. Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: The Japanese Diastolic Heart Failure study (J-DHF). Eur J Heart Fail 2013; 15: 110-118.
58. Sumita Yoshikawa W, Nakamura K, Miura D, Shimizu J, Hashimoto K, Kataoka N, et al. Increased passive stiffness of cardiomyocytes in the transverse direction and residual actin and myosin cross-bridge formation in hypertrophied rat hearts induced by chronic β-adrenergic stimulation. Circ J 2012; 77: 741-748.
59. Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005; 111: 774-781.
60. van Heerebeek L, Somsen A, Paulus WJ. The failing diabetic heart: Focus on diastolic left ventricular dysfunction. Curr Diab Rep 2009; 9: 79-86.
61. Chaturvedi RR, Herron T, Simmons R, Shore D, Kumar P, Sethia B, et al. Passive stiffness of myocardium from congenital heart disease and implications for diastole. Circulation 2010; 121: 979-988.
62. Bang ML, Centner T, Fornoff F, Geach AJ, Gotthardt M, McNabb M, et al. The complete gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system. Circ Res 2001; 89: 1065-1072.
63. Fukuda N, Wu Y, Nair P, Granzier HL. Phosphorylation of titin modulates passive stiffness of cardiac muscle in a titin isoform-dependent manner. J Gen Physiol 2005; 125: 257-271.
64. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006; 113: 1966-1973.
65. Nagueh SF, Shah G, Wu Y, Torre-Amione G, King NM, Lahmers S, et al. Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation 2004; 110: 155-162.
66. Makarenko I, Opitz CA, Leake MC, Neagoe C, Kulke M, Gwathmey JK, et al. Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res 2004; 95: 708-716.
67. Kruger M, Kotter S, Grutzner A, Lang P, Andresen C, Redfield MM, et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 2009; 104: 87-94.
68. Omori Y, Ohtani T, Sakata Y, Mano T, Takeda Y, Tamaki S, et al. L-carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. J Hypertens 2012; 30: 1834-1844.